Technical note: identifying the prostate cancer ‘superscan’ by quantitative skeletal scintigraphy
Authors:
- 1 July 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 29 (7) , 654-659
Abstract
Aim The risk of failing to recognize the false, normal pattern of the superscan is a real one, with potential consequences for diagnosis and treatment. Quantitative indices of bone activity have previously measured uptake ratios or exposure time. Such estimates from spot images have provided differentiation of the superscan from normal. More recent reports describe quantitative methods for scanning type γ-cameras, relying upon significant computation, availability of image analysis programmes or the drawing of whole skeletal regions of interest. The aim of this study was to establish a set of reference values for the evaluation of skeletal scintigraphy images, using the whole-body count alone. Materials and methods Patients underwent a routine whole-body bone study using the scanning technique. The total counts acquired during the scan were used to compare the skeletal uptake of the radiopharmaceutical between prostate patients showing superscan image patterns (n=38), prostate cancer patients with normal scans (n=40) and a control group (n=40) with normal scans, referred for reasons other than prostate cancer. Results Qualitative comparison showed patterns of avid bone uptake with diminished visualization of kidney and bladder activity in the superscan group, and normal scans in the control and prostate patient groups. Quantitation using total counts recorded directly from the whole-body bone scan showed a significantly raised value in the superscan group only (P<0.001). We have established a simple set of objective reference bands to complement visual interpretation of the scan. Conclusion The whole-body image count alone, with little or no additional processing, is a helpful discriminator for the nuclear medicine superscan. This may assist the identification of this relatively uncommon diffuse metastatic disease in men with prostate cancer and reduce the number of investigations that might otherwise be reported incorrectly as normal.Keywords
This publication has 18 references indexed in Scilit:
- 99mTc bone scintigraphy superscans: a reviewNuclear Medicine Communications, 2007
- 99Tcm(V)DMSA scintigraphy in skeletal metastases and superscans arising from various malignancies: diagnosis, treatment monitoring and therapeutic implicationsBritish Journal of Radiology, 2004
- Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatmentBJU International, 2004
- Superscan in Patients With Nasopharyngeal CarcinomaClinical Nuclear Medicine, 1996
- Antigranulocyte Antibody Bone Marrow Scans in Cancer Patients With Metastatic Bone Superscan AppearanceClinical Nuclear Medicine, 1994
- "Superscan" Appearance in Distal Renal Tubular AcidosisClinical Nuclear Medicine, 1991
- A Single Plasma Sample Method to Assess Disease Activity in Patients with Bone Metastases from Carcinoma of the ProstateBritish Journal of Urology, 1986
- An interesting bone scan in multiple myeloma—? myeloma superscanBritish Journal of Radiology, 1983
- Patterns of Diffusely Increased Skeletal Radiopharmaceutical UptakeAustralasian Radiology, 1981
- Recognition of the superscan in prostatic bone scintigraphyBritish Journal of Radiology, 1981